A detailed history of Alkeon Capital Management LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Alkeon Capital Management LLC holds 7,093,822 shares of BCRX stock, worth $53.7 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
7,093,822
Previous 7,099,484 0.08%
Holding current value
$53.7 Million
Previous $43.9 Million 22.88%
% of portfolio
0.09%
Previous 0.07%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$6.41 - $8.69 $36,293 - $49,202
-5,662 Reduced 0.08%
7,093,822 $53.9 Million
Q2 2024

Aug 13, 2024

BUY
$4.13 - $6.79 $12.4 Million - $20.4 Million
3,000,000 Added 73.18%
7,099,484 $43.9 Million
Q1 2024

May 14, 2024

BUY
$4.89 - $7.65 $11.9 Million - $18.6 Million
2,430,000 Added 145.55%
4,099,484 $20.8 Million
Q4 2023

Feb 13, 2024

SELL
$4.98 - $6.77 $14,088 - $19,152
-2,829 Reduced 0.17%
1,669,484 $10 Million
Q2 2023

Aug 11, 2023

BUY
$6.96 - $8.81 $2.81 Million - $3.55 Million
403,461 Added 31.8%
1,672,313 $11.8 Million
Q1 2023

May 12, 2023

SELL
$7.94 - $11.84 $1.72 Million - $2.57 Million
-216,965 Reduced 14.6%
1,268,852 $10.6 Million
Q4 2022

Feb 13, 2023

BUY
$10.5 - $14.2 $215,586 - $291,554
20,532 Added 1.4%
1,485,817 $17.1 Million
Q3 2022

Nov 10, 2022

BUY
$10.79 - $14.81 $3.2 Million - $4.4 Million
296,940 Added 25.42%
1,465,285 $18.5 Million
Q2 2022

Aug 15, 2022

SELL
$7.89 - $17.88 $153,855 - $348,660
-19,500 Reduced 1.64%
1,168,345 $12.4 Million
Q1 2022

May 16, 2022

BUY
$11.56 - $19.76 $13.7 Million - $23.5 Million
1,187,845 New
1,187,845 $19.3 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Alkeon Capital Management LLC Portfolio

Follow Alkeon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alkeon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alkeon Capital Management LLC with notifications on news.